COMMUNIQUÉS West-GlobeNewswire

Hemostemix Announces $2 Million Loan Facility
01/08/2019
NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES CALGARY, Alberta, Aug. 01, 2019 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“ Hemostemix ” or the “ Company ”) (TSX VENTURE: HEM; OTCQB: [...]
MRI Interventions, Inc. to Announce Second Quarter 2019 Results on August 6
01/08/2019
IRVINE, Calif., Aug. 01, 2019 (GLOBE NEWSWIRE) -- MRI Interventions, Inc. (NYSE American:MRIC), a platform neurosurgery company with products designed to deliver navigation, ablation, deep brain stimulation, biopsy and [...]
CorMedix Inc. to Report Second Quarter 2019 Financial Results and Provide a Corporate Update on August 13
01/08/2019
BERKELEY HEIGHTS, N.J., Aug. 01, 2019 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment [...]
Evolus to Report Second Quarter 2019 Financial Results and Provide a Business Update on Monday, August 12, 2019
01/08/2019
NEWPORT BEACH, Calif., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, announced today that it [...]
Progenics Pharmaceuticals Sets Second Quarter 2019 Financial Results and Business Update Call for August 9
01/08/2019
NEW YORK, Aug. 01, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today [...]
Yield10 Bioscience Chief Science Officer Dr. Kristi Snell to Present at the Plant Biology 2019 Conference
01/08/2019
WOBURN, Mass., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company that uses its “Trait Factory” to develop high value seed traits for the agriculture and food [...]
Bellerophon Completes Enrollment in Cohort 2 of Ongoing Phase 2/3 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease
01/08/2019
Initiation of Pivotal Cohort 3 Anticipated in Q1 2020 WARREN, N.J., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics [...]
Fluidigm to Automate RNA Sequencing Library Preparation Using Microfluidics Technology
01/08/2019
Automated Nanoscale RNA Library Preparation for Next-Generation Sequencing to Deliver Significant Savings and Workflow Efficiency for the Molecular Laboratory SOUTH SAN FRANCISCO, Calif., Aug. 01, 2019 (GLOBE NEWSWIRE [...]
Ultragenyx Announces Submission of New Drug Application to FDA for UX007 (triheptanoin) for Treatment of Long-Chain Fatty Acid Oxidation Disorders
01/08/2019
NOVATO, Calif., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare diseases, today [...]
Agritek Holdings Inc. Announces Execution of Revised Term Sheet for Cash Infusion of Up to $5 Million Dollars From Private Banking Partner and Equity Line for Targeted California Manufacturing Acquisition
01/08/2019
LOS ANGELES, CA, Aug. 01, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Agritek Holdings, Inc. (OTC: AGTK) www.AgritekHoldings.com , a fully integrated, active real estate investor for the cannabis sector and consultant [...]
I-Mab Biopharma and TRACON Pharmaceuticals Announce Dosing of the First Patient in the U.S. Phase 1 Clinical Trial of the CD73 Antibody TJD5 in Patients with Advanced Solid Tumors
01/08/2019
SHANGHAI, China and SAN DIEGO, Aug. 01, 2019 (GLOBE NEWSWIRE) -- I-Mab Biopharma (I-Mab), a China and U.S.-based clinical stage biopharmaceutical company exclusively focusing on the discovery and development of [...]
Catalyst Pharmaceuticals Announces Its Support of Spinal Muscular Atrophy Awareness Month
01/08/2019
CORAL GABLES, Fla., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with [...]
Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-105
01/08/2019
-ET-105 assigned Prescription Drug User Fee Act (PDUFA) target action date of March 17, 2020 DEER PARK, Ill., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical [...]
Alder BioPharmaceuticals® to Present at Canaccord Genuity 39th Annual Growth Conference
01/08/2019
BOTHELL, Wash., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today [...]
Iterum Therapeutics to Present at the Canaccord Genuity 39th Annual Growth Conference
01/08/2019
DUBLIN, Ireland and CHICAGO, Aug. 01, 2019 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat [...]
Intellia Therapeutics Announces Second Quarter 2019 Financial Results and Company Update
01/08/2019
NTLA-2001: Intends to submit an investigational new drug application in mid-2020 for lead in vivo program for the treatment of transthyretin amyloidosis On track to nominate first engineered cell therapy development [...]
Kaleido Biosciences Reports Second Quarter 2019 Financial Results and Provides Corporate Update
01/08/2019
LEXINGTON, Mass., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to leveraging the potential of the microbiome organ to [...]
Repligen Reports Second Quarter 2019 Financial Results and Updates Full Year 2019 Financial Guidance
01/08/2019
Reports record quarterly revenue of $70.7 million, representing 48% year-over-year growth and 46% organic growth Raises revenue guidance to $264-$268 million for full year 2019, representing 29%-31% organic growth [...]
New Executive Team Announced at Adaptimmune
01/08/2019
- Adrian Rawcliffe to assume CEO role from September 1, 2019 - - John Lunger promoted to Chief Patient Supply Officer from August 1, 2019, as Adaptimmune gears up for commercial delivery of products to patients – - [...]

Pages